| Literature DB >> 26347225 |
Chen-Pang Hou1, Yu-Hsiang Lin1, Meng-Chiao Hsieh2, Chien-Lun Chen1, Phei-Lang Chang1, Ying-Chen Huang3, Ke-Hung Tsui1.
Abstract
OBJECTIVE: The purpose of this study was to prospectively investigate the degree of pain experienced by the patients receiving transrectal ultrasonography (TRUS) of the prostate by applying a visual analog scale. We also identified the clinical parameters influencing pain during the TRUS examination.Entities:
Keywords: TRUS; VAS; benign prostate hyperplasia; digital examination; pain score; transrectal; ultrasound
Year: 2015 PMID: 26347225 PMCID: PMC4556256 DOI: 10.2147/PPA.S83073
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Image shows artifact caused by stool stored in the rectum and interfered with the image quality. The examiner cannot easily measure the prostate sagittal length.
Characteristics of the study population
| Variable (number =498) | n (range) |
|---|---|
| Median age (years) | 63 (43–87) |
| Median BMI | 24.98 (16.8–47.06) |
| Median PSA (ng/mL) | 5.03 (0.1–398.7) |
| Median prostate volume (mL) | 32.40 (10.3–162.00) |
| Median prostatic sagittal length (cm) | 4.50 (2.42–7.50) |
| Mean pain score (VAS) | 2.87±2.02 (0–9) |
Abbreviations: BMI, body mass index; PSA, prostate-specific antigen; VAS, visual analog scale.
Figure 2Distribution of pain score.
Abbreviation: VAS, visual analog scale.
Figure 3Kolmogorov–Smirnov test results showing that the pain score was normally distributed.
Comparison of patients’ numerical variables between pain score ≤3 and pain score ≥4
| Characteristics | Pain score ≤3 mean ± SD | Pain score ≥4 mean ± SD | |
|---|---|---|---|
| Age (years) | 65.79±10.92 | 63.04±11.67 | 0.0293 |
| BMI | 25.11±3.86 | 25.20±3.76 | 0.9314 |
| Prostate volume (gm) | 37.41±20.39 | 43.04±24.45 | 0.0161 |
| Prostate sagittal length (cm) | 4.56±0.78 | 4.69±0.94 | 0.0415 |
| PSA (ng/mL) | 3.24±2.17 | 4.85±3.82 | 0.8216 |
Notes: Comparisons were made using Mann–Whitney U-test.
Indicates significant difference.
Abbreviations: BMI, body mass index; PSA, prostate-specific antigen; SD, standard deviation.
Comparison of patients’ qualitative variables between pain score ≤3 and pain score ≥4
| Characteristics | Pain score ≤3 (%) | Pain score ≤4 (%) | |
|---|---|---|---|
| Previous TRUS experience (%) | 23.85% | 13.33% | 0.0427 |
| Group 2 (%) | 60.48% | 34.91% | <0.0001 |
| External hemorrhoids (%) | 26.67% | 59.09% | <0.0001 |
| Prostate calcification (%) | 22.11% | 36.19% | 0.0893 |
| Previous anal operation (%) | 6.96% | 31.63% | <0.0001 |
| Stool artifact (%) | 11.79% | 22.85% | 0.0068 |
Notes: Comparisons were made using χ2 test.
Indicates significant difference.
Abbreviation: TRUS, transrectal ultrasound of the prostate.
Figure 4Significantly lower pain scores of group 2 patients compared with those of group 1 patients.
Abbreviation: VAS, visual analog scale.
Multivariate analysis for the pain associated with TRUS using linear regression analysis
| Variable | β | SE (β) | |
|---|---|---|---|
| Age (continuous variable) | −0.01381 | 0.0075 | 0.0671 |
| BMI (continuous variable) | −1.001942 | 0.0209 | 0.9258 |
| Prostate volume (continuous variable) | −0.00131 | 0.0020 | 0.6571 |
| Prostate sagittal length (continuous variable) | 0.005547 | 0.0021 | 0.0072 |
| PSA (continuous variable) | 0.00002831 | <0.001 | 0.717 |
| Group 2 (vs group 1) | −0.4484 | 0.1570 | 0.0045 |
| Previous TRUS experience (vs absence of previous TRUS experience) | −0.4234 | 0.1932 | 0.0289 |
| External hemorrhoids (vs absence of external hemorrhoids) | 1.261 | 0.1736 | <0.0001 |
| Previous anal operation history (vs absence of anal operation history) | 1.568 | 0.2476 | <0.0001 |
| Prostate calcification (vs no calcification) | 0.4528 | 0.1800 | 0.1122 |
| Stool artifact (vs no stool artifact) | 0.7174 | 0.2310 | 0.0021 |
Notes:
Indicates significant difference.
Abbreviations: TRUS, transrectal ultrasonography of the prostate; β, regression coefficient; SE, standard error; BMI, body mass index; PSA, prostate-specific antigen; vs, versus.